ClinicalTrials.gg
CompletedNCT07549386Updated Apr 29, 2026

Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.

A Phase 3 interventional study of Etoricoxib 90 mg + diacerein 50 mg and Meloxicam 15 mg + diacerein 50 mg in Pain Management and Osteoarthritis, sponsored by Laboratorios Liomont. Completed at 4 sites in Mexico. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Laboratorios Liomont · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled May 2024, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Osteoarthritis with a site in Mexico — 2 open to participants now, 3 under way, 1 of them phase 3. Osteoarthritis · Mexico.

Enrollment
8th of 18
123 · median 117
Started
2024
with 2 others
Phase 3
7 of 20
none open now
Registered
19th of 20
by date
Lead sponsor
1 of 20
Laboratorios Liomont

Among the 20 studies in Osteoarthritis with a site in Mexico, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 3, and was the 19th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

2 of the 20 studies in Osteoarthritis with a site in Mexico are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Osteoarthritis with a site in Mexico, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if fixed-dose combination etoricoxib 90 mg + diacerein 50 mg capsule works to treat knee/hip osteoarthritis-associated pain in adults. It will also learn about the safety of the drug. The main questions it aims to answer are:

Does etoricoxib+diacerein reduce pain intensity as per WOMAC scale after 60 days? What medical problems do participants have when taking etoricoxib 90 mg+diacerein 50 mg capsule for 60 days? Researchers will compare the test drug etoricoxib 90 mg+diacerein 50 mg capsule to an active comparator (meloxicam 15 mg + diacereina 50 mg) to see if drug ABC works to treat pain in patients with osteoarthritis.

Participants will:

Take drug the test or comparator drugs every day for 60 days. Visit the clinic once a month for health and outcomes follow-up. Keep a diary of their symptoms, pain intensity, WOMAC scale, adverse events, rescue medication use, other used drugs, and treatment adherence.

03

Conditions studied

  • Pain Management
  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult men and women (≥ 18 and ≤ 65 years of age).
  2. Patients who agree to participate in the study by signing the form.
  3. Patients with a clinical diagnosis of knee or hip OA according to the American College of Rheumatology criteria with radiographic evidence of OA (K-L score ≥2) in the index joint (defined as the joint with OA being evaluated in this study).

    1. A joint previously treated by joint replacement surgery cannot be considered an index joint.
    2. A joint surgically intervened within the previous year cannot be considered an index joint.
    3. If a patient has a K-L score of ≥2 in more than one joint (knees or hip), the index joint will be the joint with the highest WOMAC pain subscore.
    4. If two or more of the patient's joints (knees or hip) have a K-L score of ≥2 and the same WOMAC pain subscore, the index joint will be the joint with the highest K-L score.
    5. If two or more joints (knees or hip) have a K-L score of ≥2, the same WOMAC pain subscore, and the same K-L score, the investigator may choose one of these joints as the index joint based on medical judgment.
  4. Patients with moderate to severe pain in the index joint defined as a WOMAC pain subscore of ≥4.
  5. Patients who, in the investigator's medical judgment, can discontinue current analgesic medications and are willing to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Patients with allergy or to the study medications (including the rescue medication) or to any of their .
  2. Patients with a ≥ 39.
  3. Patients with a history of rapidly progressive hip OA.
  4. Patients with a history of inflammatory joint disease other than OA (e.g., rheumatoid arthritis, lupus erythematosus, psoriatic arthritis, pseudogout, acute gout, joint infections) or seronegative spondyloarthropathy, Paget's disease of the spine, pelvis, or femur, neuropathic disorders, multiple sclerosis, fibromyalgia, spinal cord tumors or infections, or renal osteodystrophy.
  5. History of arthropathy (osteonecrosis, insufficiency fracture of subchondral bone, rapidly progressive osteoarthritis type 1 or type 2), neuropathic joint arthropathy, hip dislocation, knee dislocation, extensive subchondral cysts, significant bone collapse, significant loss of bone mass, or pathological fractures.
  6. Scheduled joint replacement surgery to be performed during the study period, or arthroscopic procedures within 6 months prior to study initiation.
  7. Trauma to the index joint within 30 days prior to the screening visit.
  8. Use of systemic within 30 days prior to the screening visit or intra-articular corticosteroids in the index joint within 12 weeks prior to the screening visit.
  9. Concomitant use of medications with laxative effects.
  10. Continuous oral treatment (at least 90 days) with a SYSADOA medication (chondroitin sulfate, glucosamine sulfate, diacerein, or other) within 3 months before the start of the study.
  11. Use of monoamine reuptake inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors for pain treatment within 4 weeks prior to the screening visit.
  12. History of peptic ulcer or gastrointestinal bleeding within 12 months prior to the screening visit and/or medical for the use of NSAIDs.
  13. Severe gastrointestinal disorders, including persistent diarrhea (≥3 bowel movements/24 hours).
  14. Renal insufficiency (serum creatinine ≥1.8 mg/dL or 2+ proteinuria on a test or a \<30 mL/min).
  15. Liver enzyme levels (, AST, GST) elevated ≥2.5 times the at the time of screening.
  16. History or presence of cardiovascular diseases (e.g., second- or third-degree heart block, first-degree heart block with abnormal QRS or bifascicular block, history of uncontrolled arterial hypertension, congestive heart failure classified as stage II-IV, (TIA) or stroke within 12 months prior to the screening visit, or myocardial infarction or acute coronary syndromes or evidence of peripheral vascular insufficiency with claudication within 6 months prior to the screening visit).
  17. History of other comorbidities that, in the investigator's judgment, could affect the subject's participation in the study, their safety, or the outcome of the study variables.
  18. Current history of alcoholism and/or drug abuse.
  19. Current participation in a clinical research study evaluating another drug or having received another investigational product within 30 days prior to the screening visit.
  20. Women with a positive pregnancy test at the time of screening or who are breastfeeding.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Etoricoxib 90 mg + diacerein 50 mg

    One capsule

    Drug: Etoricoxib 90 mg + diacerein 50 mg

  • Active comparator
    Meloxicam 15 mg + diacerein 50 mg

    One capsule

    Drug: Meloxicam 15 mg + diacerein 50 mg

Interventions

  • DrugEtoricoxib 90 mg + diacerein 50 mg

    Drug page: Etoricoxib

    Once a day for 60 days

  • DrugMeloxicam 15 mg + diacerein 50 mg

    Drug page: Meloxicam

    Once a day for 60 days.

06

What researchers measure

Primary outcomes

  1. Pain intensity change

    Pain intensity change measured by 100 mm - Visual Analogue Scale. A reduction of 20 mm or higher means a clinically relevant outcome.

    Time frame: At 60 days from baseline

Secondary outcomes

  1. Osteoarthritis index change

    Western Ontario and McMaster Universities Arthritis Index (WOMAC) 1. Pain (0-20 points) 2. Stiffness (0-8 points) 3. Functional capacity (0-68 points) Lower scores at the end of the intervention mean a better outcome.

    Time frame: At 60 days from baseline

  2. Use of rescue medication

    Proportion of patients need to use rescue medication.

    Time frame: At 60 days from baseline.

  3. Quality of Life

    Quality of Life will be measured using the Short Form-12 Health Survey (SF-12). SF-12 health survey, which yields two norm-based summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each score is standardized to a general population mean of 50 (SD = 10), where higher scores indicate better health-related quality of life."

    Time frame: At 60 days from baseline.

  4. Safety and tolerability

    Proportion of patients experienced at least one adverse event.

    Time frame: At 60 days from informed consent sign.

07

Study locations

4 sites
  • Grupo Médico ASSET, S.C.
    Mexico City, Mexico City 03100, Mexico
  • RM Pharma Specialists S.A. de C.V.
    Mexico City, Mexico City 03100, Mexico
  • Ainpad, S.C.
    Morelia, Michoacán 58350, Mexico
  • Hospital Centro Quirúrgico Nogalar, S.A. de C.V.
    Monterrey, Nuevo León 66484, Mexico
08

References and documents

Publications

  • Kongtharvonskul J, Anothaisintawee T, McEvoy M, Attia J, Woratanarat P, Thakkinstian A. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res. 2015 Mar 13;20(1):24. doi: 10.1186/s40001-015-0115-7. PubMed 25889669 ↗
  • Cuomo A, Bimonte S, Forte CA, Botti G, Cascella M. Multimodal approaches and tailored therapies for pain management: the trolley analgesic model. J Pain Res. 2019 Feb 19;12:711-714. doi: 10.2147/JPR.S178910. eCollection 2019. PubMed 30863143 ↗
  • Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010 Apr;2(2):95-104. doi: 10.1177/1759720X09359104. PubMed 22870441 ↗
  • Lespasio MJ, Sultan AA, Piuzzi NS, Khlopas A, Husni ME, Muschler GF, Mont MA. Hip Osteoarthritis: A Primer. Perm J. 2018;22:17-084. doi: 10.7812/TPP/17-084. PubMed 29309269 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Mar 2025, 10 months.

Of 60 industry-sponsored phase 3 interventional studies under Osteoarthritis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 10 months is below that.

Counting every sponsor, half of 84 studies reached it within 17 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 24, 2026
StartActual
May 24, 2024
Primary completionActual
Mar 27, 2025
CompletionActual
Oct 15, 2025
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07549386
Lead sponsor
Laboratorios Liomont
Collaborators
EPIC Research CRO
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
May 24, 2024
Primary completion
Mar 27, 2025
Completion
Oct 15, 2025
Last update
Apr 29, 2026

Study contacts

Livan Delgado Roche, Ph.D.
study director · Laboratorios Liomont

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion